SIRT2 and breast cancer: Compound 26, the most potent of these next-generation TM pseudopeptides, exhibited on-target Sirt2 inhibition in MCF7 breast cancer cells, as demonstrated by increased acetylation of perinuclear α-tubulin; Compound 26 also decreased MCF7 cell migration, a proxy for metastatic potential [188].